A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study are to determine whether a test dose program for taxanes will reduce the rate and/or severity of hypersensitivity reactions (HSR); and to determine whether a test dose program for taxanes will result in cost reduction due to decreased drug wastage.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New Mexico Cancer Care Alliance
• Treatments: Docetaxel; Paclitaxel; Taxane

Criteria

Inclusion Criteria:

• Patient must sign informed consent

• Patient must be greater than 18 years of age

• Patient must be receiving his/her first dose of either Taxol or Taxotere

• Patient must have received routine premedications for hypersensitivity reactions